Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?

被引：2
|
作者：
Fenchel, Klaus [1 ,2 ]
Dale, Stephen P. [3 ]
Dempke, Wolfram C. M. [3 ,4 ]
机构：
[1] Med Sch Hamburg MSH, Hamburg, Germany
[2] Praxisklin Saalfeld Saale, Saalfeld, Germany
[3] Kyowa Kirin Pharmaceut Dev Ltd, Galashiels, Scotland
[4] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Haematol & Oncol, Munich, Germany
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2016年 / 5卷 / 04期
关键词：
RANDOMIZED CONTROLLED-TRIAL; MUTANT LUNG-CANCER; 1ST-LINE TREATMENT; PHASE-3; TRIAL; DOUBLE-BLIND; OPEN-LABEL; CHEMOTHERAPY; GEFITINIB; AFATINIB; ADENOCARCINOMA;
D O I：
10.21037/tlcr.2016.07.01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：373 / 376
页数：4
相关论文
共 50 条
  • [11] Effects of high-dose tyrosine kinase inhibitor (TKI) treatment in vitro are mediated by prolonged intracellular TKI exposure
    Blum, M.-C.
    Dziadosz, M.
    Heidel, F.
    Fischer, T.
    Lipka, D. B.
    ONKOLOGIE, 2010, 33 : 143 - 143
  • [12] Adverse events of sequential tyrosine kinase inhibitor following immune checkpoint inhibitor in advanced NSCLC patients
    Shimoda, Yukiko
    Miyakoshi, Jun
    Yoshida, Tatsuya
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2022, 33 : S482 - S483
  • [13] The predictive value of serum tumour markers in Tyrosine Kinase Inhibitor (TKI) treatment for advanced non-small cell lung cancer (NSCLC)
    Pearmain, L.
    Crawford, S. M.
    LUNG CANCER, 2011, 71 : S5 - S5
  • [14] Thoracoscopic lobectomy following neoadjuvant tyrosine kinase inhibitor treatment
    Chudgar, Neel P.
    Jones, David R.
    JTCVS TECHNIQUES, 2021, 7 : 294 - 297
  • [15] Hepatitis B virus (VHB) reactivation following treatment with Tyrosine Kinase Inhibitors (TKI)
    Gouraud, A.
    Default, A.
    Lillo-Le Louet, A.
    Chartier, C.
    Dumortier, J.
    Vial, T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 24 - 24
  • [16] IMPACT OF TYROSINE KINASE INHIBITOR (TKI) DOSAGE MODIFICATIONS ON PROGRESSION-FREE SURVIVAL (PFS) IN THE TREATMENT OF EGFR-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)
    Carrasquilla, S.
    Bi, Y.
    Gu, W.
    Ayyoub, A.
    Fletcher, E. Pfuma
    Liu, J.
    Ramamoorthy, A.
    Shord, S.
    Zineh, I.
    Madabushi, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S21 - S21
  • [17] Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration - a Swedish nationwide retrospective study
    Lauppe, Rosa
    Nilsson, Fredrik O. L.
    Wahl, Hanna Fues
    Lilja, Mathias
    Vikstrom, Anders
    Asanin, Sandra T.
    ACTA ONCOLOGICA, 2022, 61 (11) : 1354 - 1361
  • [18] A MECHANISM FOR INDUCTION OF APOPTOSIS FOLLOWING SHORT-TERM TYROSINE KINASE INHIBITOR (TKI) TREATMENT: INTRACELLULAR RETENTION OF TKI RESULTS IN PROLONGED CELLULAR TKI EXPOSURE AND INHIBITION OF KEY SIGNALING PATHWAYS
    Lipka, D.
    Blum, M. C.
    Dsiadosz, M.
    Heidel, F.
    Fischer, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 351 - 351
  • [19] EGFR MUTATION AND TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN A DANISH (CAUCASIAN) POPULATION OF ADVANCED NSCLC PATIENTS AT ODENSE UNIVERSITY HOSPITAL 2010-11
    Kjeldsen, R.
    Hansen, K. H.
    Olsen, K. E.
    Hansen, N. G.
    Hansen, O.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S66 - S67
  • [20] ROBOTIC PARTIAL NEPHRECTOMY FOLLOWING NEOADJUVANT TYROSINE KINASE INHIBITOR TREATMENT
    White, Michael A.
    Spana, Gregory
    Hillyer, Shahab
    Rini, Brian I.
    Campbell, Steven C.
    Kaouk, Jihad H.
    JOURNAL OF UROLOGY, 2011, 185 (04): : E412 - E412
12345